Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of “Hold” from Brokerages

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have received a consensus rating of “Hold” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $15.17.

A number of equities research analysts have commented on ELAN shares. Piper Sandler dropped their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, March 6th. Barclays cut their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. UBS Group cut their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Leerink Partners began coverage on Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price target on the stock. Finally, Stifel Nicolaus reduced their price objective on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, February 21st.

Elanco Animal Health Trading Down 3.8 %

ELAN opened at $10.40 on Wednesday. The business has a fifty day moving average price of $11.23 and a 200 day moving average price of $12.42. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health has a 12 month low of $10.03 and a 12 month high of $18.80. The stock has a market capitalization of $5.14 billion, a price-to-earnings ratio of 25.99, a PEG ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the firm posted $0.08 earnings per share. The business’s quarterly revenue was down 1.4% compared to the same quarter last year. Sell-side analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Lawrence Erik Kurzius purchased 10,000 shares of the firm’s stock in a transaction on Tuesday, March 11th. The shares were bought at an average cost of $10.20 per share, with a total value of $102,000.00. Following the purchase, the director now directly owns 111,459 shares of the company’s stock, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.57% of the company’s stock.

Institutional Trading of Elanco Animal Health

A number of hedge funds have recently bought and sold shares of ELAN. Steward Partners Investment Advisory LLC boosted its stake in Elanco Animal Health by 28.3% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company’s stock worth $124,000 after buying an additional 2,264 shares during the last quarter. DDD Partners LLC purchased a new position in shares of Elanco Animal Health during the 4th quarter worth about $5,974,000. Geode Capital Management LLC grew its holdings in Elanco Animal Health by 0.8% in the third quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock valued at $115,623,000 after purchasing an additional 65,303 shares during the period. Atom Investors LP increased its position in Elanco Animal Health by 310.3% during the third quarter. Atom Investors LP now owns 345,855 shares of the company’s stock worth $5,081,000 after purchasing an additional 261,559 shares during the last quarter. Finally, Harbor Capital Advisors Inc. increased its position in Elanco Animal Health by 24.0% during the fourth quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock worth $13,135,000 after purchasing an additional 209,734 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.